0.26
-0.009(-3.41%)
Currency In GBp
Address
3140 Rowan Place
Oxford, OX4 2WB
United Kingdom of Great Britain and Northern Ireland
Phone
44 1865 518 910
Sector
Healthcare
Industry
Biotechnology
Employees
51
First IPO Date
December 06, 2016
| Name | Title | Pay | Year Born |
| Paul Leslie Stockdale | CFO & Executive Director | 205,000 | 1975 |
| Alexandre Akoulitchev Ma | Chief Scientific Officer & Executive Director | 237,000 | 1962 |
| David Blum | Senior Vice President of Marketing | 0 | N/A |
| Ewan Hunter | Chief Data Officer | 0 | N/A |
| Iain Gladstone Ross | Executive Chairman | 0 | 1954 |
| Thomas G. Guiel | Chief Operating Officer | 0 | N/A |
| T. Demain | Company Secretary | 0 | N/A |
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.